Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus

被引:13
|
作者
Costa, Nadia Lago [1 ]
Goncalves, Julie Ane Maria [1 ]
de Lima, Sara Lia Goncalves [1 ]
de Arruda, Jose Alcides Almeida [2 ]
Miranda, Ana Carolina Campos [1 ]
Mesquita, Ricardo Alves [1 ,2 ]
da Silveira, Ericka Janine Dantas [3 ]
Batista, Aline Carvalho [1 ]
机构
[1] Univ Fed Goias, Sch Dent, Dept Stomatol Oral Med & Oral Pathol, Praca Univ S-N,Setor Univ, BR-74605220 Goiania, Go, Brazil
[2] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG, Brazil
[3] Univ Fed Rio Grande do Norte, Dept Dent, Postgrad Program Odontol Sci, Natal, RN, Brazil
关键词
immunogenicity; immunohistochemical; lichen planus; mouth diseases; programmed cell death-1 ligand-2 protein; T-lymphocyte receptor; MALIGNANT-TRANSFORMATION; T-CELLS; EVASION MECHANISMS; EXPRESSION; MICROENVIRONMENT; PATHWAY; LESIONS; B7-DC;
D O I
10.1111/odi.13344
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective To investigate the expression of programmed death-ligands 1 and 2 (PD-L1, PD-L2), programmed death-1 (PD-1), CD8 and granzyme B (GrB), as well as its correlation with the severity of oral lichen planus (OLP). Materials and Methods In a collaborative study, 33 cases of OLP were evaluated according to the latest criteria proposed by the American Academy of Oral and Maxillofacial Pathology (AAOMP/2016) and were submitted to immunohistochemistry. Positivity was measured semiquantitatively (PD-L1, PD-L2) and quantitatively (PD-1, CD8, GrB). The severity of OLP was assessed according to clinical subtype, symptomatology and response to corticosteroid therapy. Results Most OLPs were considered to be negative for PD-L1 (66.6%), but high expression of PD-L2 (96.9%) by keratinocytes and immunoinflammatory cells was observed. PD-1(+) cell density/mm(2) was reduced compared to CD8(+) cells. A low cytotoxic immune response (CD8:GrB ratio) was also demonstrated. Interestingly, there were fewer GrB(+) cells in the intraepithelial region in reticular OLP compared to erosive/bullous OLP. Conclusions PD-L1/PD-1 pathways appear to be compromised in OLP due to low PD-L1 expression in most samples. In contrast, PD-L2 overexpression associated with a possible regulation of the cytotoxic immune response suggests an immune tolerance that may contribute to the chronic profile of OLP.
引用
收藏
页码:1246 / 1254
页数:9
相关论文
共 50 条
  • [1] PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
    Dimitrios Mathios
    Jacob Ruzevick
    Christopher M. Jackson
    Haiying Xu
    Sagar Shah
    Janis M. Taube
    Peter C. Burger
    Edward F. McCarthy
    Alfredo Quinones-Hinojosa
    Drew M. Pardoll
    Michael Lim
    Journal of Neuro-Oncology, 2015, 121 : 251 - 259
  • [2] PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
    Mathios, Dimitrios
    Ruzevick, Jacob
    Jackson, Christopher M.
    Xu, Haiying
    Shah, Sagar
    Taube, Janis M.
    Burger, Peter C.
    McCarthy, Edward F.
    Quinones-Hinojosa, Alfredo
    Pardoll, Drew M.
    Lim, Michael
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (02) : 251 - 259
  • [3] Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
    Dimitrios Mathios
    Jacob Ruzevick
    Christopher M. Jackson
    Haiying Xu
    Sagar R. Shah
    Janis M. Taube
    Peter C. Burger
    Edward F. McCarthy
    Alfredo Quinones-Hinojosa
    Drew M. Pardoll
    Michael Lim
    Journal of Neuro-Oncology, 2016, 128 : 183 - 183
  • [4] PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
    Ghiotto, Marguerite
    Gauthier, Laurent
    Serriari, Nacer
    Pastor, Sonia
    Truneh, Alemseged
    Nunes, Jacques A.
    Olive, Daniel
    INTERNATIONAL IMMUNOLOGY, 2010, 22 (08) : 651 - 660
  • [5] PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer
    Yang, Shijie
    Zhang, Qiuyang
    Liu, Sen
    Wang, Alun R.
    You, Zongbing
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2016, 4 (01): : 1 - 8
  • [6] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Magiera, Katarzyna
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    STRUCTURE, 2017, 25 (08) : 1163 - 1174
  • [7] PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
    Carter, Laura L.
    Leach, Michael W.
    Azoitei, Mihai L.
    Cui, Junqing
    Pelker, Jeffrey W.
    Jussif, Jason
    Benoit, Steve
    Ireland, Gretchen
    Luxenberg, Deborah
    Askew, G. Roger
    Milarski, Kim L.
    Groves, Christopher
    Brown, Tom
    Carito, Brenda A.
    Percival, Karen
    Carreno, Beatriz M.
    Collins, Mary
    Marusic, Suzana
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 182 (1-2) : 124 - 134
  • [8] Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors
    Pinto, Navin
    Park, Julie R.
    Murphy, Erin
    Yearley, Jennifer
    McClanahan, Terri
    Annamalai, Lakshmanan
    Hawkins, Douglas S.
    Rudzinski, Erin R.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (11)
  • [9] Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).
    Gennatas, Spyridon
    Fernandez, Angeles Montero
    Bowman, Alex
    Ronquillo, John
    Nicholson, Andrew G.
    Popat, Sanjay
    Bowcock, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Expression of PD-1, PD-L1, and PD-L2 in the liver in autoirnmune liver diseases
    Mataki, Norikazu
    Kikuchi, Kentaro
    Kawai, Toshihiro
    Higashiyama, Masaaki
    Okada, Yoshikiyo
    Kurihara, Chle
    Hokari, Ryota
    Kawaguchi, Atsushi
    Nagao, Shigeaki
    Kondo, Toshiro
    Itoh, Kazuro
    Miyakawa, Hiroshi
    Miura, Soichiro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (02): : 302 - 312